Business groups fight Biden’s $3.5T budget
They want lawmakers to oppose Democrats’ wide-ranging bill as drafting deadline nears
“The chamber will do everything we can to prevent this tax-raising, job-killing reconciliation bill from becoming law.” Suzanne Clark CEO of the U.S. Chamber of Commerce
WASHINGTON – As some crucial Democrats express concerns over President Joe Biden’s $3.5 trillion budget that is the centerpiece of his domestic agenda, major business groups are fighting various parts of the wide-ranging bill. h Advocacy groups are drawing battle lines in opposition to parts of the bill aiming to raise taxes on corporations and wealthy individuals, lower prices on prescription drugs and combat climate change. The fights that could trim or threaten to kill the legislation will play out in the coming days and weeks as committees rush to meet a Wednesday deadline for drafting legislation.
Groups such as the U.S. Chamber of Commerce, the National Association of Manufacturers and the Business Roundtable contend raising corporate taxes to pay for the massive package will hurt the economy by discouraging investment and spurring inflation.
Specific industries also have raised concerns about their corners of the proposal. Pharmaceutical manufacturers oppose a House strategy to allow Medicare to negotiate drug prices. Energy groups oppose a potential tax on methane emissions, a greenhouse gas that traps more heat than carbon dioxide.
The opposition contrasts sharply with widespread support for a $1.2 trillion infrastructure package for roads and bridges. The Senate approved that package on a bipartisan, 69-30 vote. It now awaits a House vote.
Democratic leaders in both chambers of Congress are trying to approve the $3.5 trillion worth of Biden’s domestic priorities in what they call a once-in-a-generation effort. Among other aims, Biden wants the bill to include free prekindergarten and community college and dedicate billions for caregiving and child care.
The Democrats’ strategy avoids a Senate filibuster and wouldn’t need Republican votes.
“We will have a great bill that will honor the values of the president and his vision,” House Speaker Nancy Pelosi, D-Calif., told reporters last week.
But unified Republican opposition in the narrowly divided House and Senate means just a few Democratic defectors could scuttle what is potentially the biggest budget bill ever debated. Industry groups are wielding big-ticket advertising and grassroots lobbying to persuade lawmakers to oppose the legislation.
“We’ll be using any tool available to us,” Aric Newhouse, senior vice president for policy and govern
ment relations at the National Association of Manufacturers, said.
The key to funding Biden’s priorities – and to the opposition they have generated – is his proposal to essentially overturn the Trump administration tax cuts on corporations and on individuals earning more than $400,000 a year.
Biden and dozens of progressive advocacy groups are pursuing the tax hikes in order to pay for priorities such as federally subsidized prekindergarten and community college, paid family leave and expanding Medicare with vision, dental and hearing benefits.
“Somebody has got to pay. And when those who can afford to pay aren’t paying anywhere near their fair share, it means you all pay more,” Biden said Sept. 3. “For those big corporations that don’t want things to change, my message is this: It’s time for working families – the folks who built this country – to have their taxes cut.”
Lawmakers are still working out the details on the corporate rate, which dropped from 35% to 21% under the 2017 law, and on individuals. Biden proposed a 28% corporate rate. The House Ways and Means Committee released draft legislation Monday calling for a 26.5% top corporate tax rate.
After the Senate and House approved the budget framework in August, corporate opposition was immediate.
Suzanne Clark, CEO of the U.S. Chamber of Commerce, said the package would “dramatically expand the size and scope of government through record levels of inflationary spending and impose massive tax increases that will halt America’s fragile economic recovery.”
“The chamber will do everything we can to prevent this tax-raising, job-killing reconciliation bill from becoming law,” she said.
The National Association of Manufacturers released a study that calculated 1 million jobs would be lost in the first two years under a tax increase to a 25% corporate rate. The economy would decline by $169 billion in 2026, according to the study by Rice University economists John Diamond and George Zodrow. And companies would invest $70 billion less in 2026, the study found.
The association also released a survey Thursday that found 94% of manufacturers said higher taxes would hurt their businesses. The group launched a sixfigure advertising campaign, with print, radio and digital ads in Washington and key states, calling on Congress to oppose tax increases.
“This survey delivers an urgent warning for lawmakers: if you raise taxes on manufacturers, there will be no avoiding widespread job losses, slower growth and wage stagnation,” Jay Timmons, CEO of the National Association of Manufacturers, said in a statement.
Besides the broad tax implications, industries and lawmakers voiced concerns about specific provisions in the legislation, particularly the cost of prescription drugs.
One contentious element that Congress has debated – and killed – for decades aims to allow Medicare to negotiate the price of prescription drugs. The goal is to reduce costs for the elderly and people with disabilities who participate in the Medicare prescription program that Congress created in 2003.
“We’re going to bring down the cost of prescription drugs by allowing Medicare to finally be able to negotiate drug prices,” Biden said on Sept. 3.
AARP sponsored a seven-figure television and digital ad campaign endorsing Medicare negotiations in states such as Arizona, Delaware, New Jersey and Pennsylvania. AARP was also publicizing the debate through social media, tele-town halls with elected officials and in its publications.
The proposal is that Medicare could negotiate lower prices because 45 million people participate in its drug program. But the industry through Pharmaceutical Research and Manufacturers of America says private insurers that administer the program already negotiate prices. Steeper savings would require the threat of refusing to pay for medications, which is unpopular with patients seeking cutting-edge drugs such as those for cancer, manufacturers say.
Lawmakers haven’t detailed yet how they would authorize Medicare negotiations. But Pelosi said the strategy could mirror one the House approved in 2019. Under that proposal, Medicare would effectively cap the amount it paid for drugs at 120% of the average price in Australia, Canada, France, Germany, Japan and the United Kingdom. That would reduce the price of more expensive drugs in America and reduce federal spending by an estimated $456 billion over a decade, according to the nonpartisan Congressional Budget Office.
Pelosi told reporters last week this strategy would be included in the budget. “We are all for that,” she said.
A sticking point has been how to enforce negotiations if a drugmaker chose not to participate. The previous House legislation said Medicare could impose an excise tax on a medication to nearly double its price.
But the Senate ignored the House bill two years ago. Another enforcement option lawmakers have debated in the past would be if Medicare refused to pay for certain drugs because of their price.
The industry argues that making drugs unavailable – either because manufacturers refuse to sell for the lower price or because Medicare refuses to pay for them – angers patients looking for cutting-edge drugs.
“While some lawmakers talk about ‘negotiation,’ what they really mean is government price-setting, and the American people oppose that approach when they learn it will lead to less access to medicines and fewer new treatments,” said Steve Ubl, CEO of PhRMA.